Treatment of atrial fibrillation

JAMA - Journal of the American Medical Association

Volumn 314, Issue 3, 2015, Pages 278-288

  Prystowsky, Eric N ^a   Padanilam, Benzy J ^a   Fogel, Richard I ^a  

^a ST VINCENT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGOXIN; DOFETILIDE; FLECAINIDE; IBUTILIDE; PLACEBO; PROPAFENONE; SOTALOL;

ARTIFICIAL HEART PACEMAKER; ATRIAL FIBRILLATION; BIVENTRICULAR ASSIST DEVICE; CARDIOVASCULAR MORTALITY; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONTROL STRATEGY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; LIVER TOXICITY; LUNG TOXICITY; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PACEMAKER IMPLANTATION; PATHOPHYSIOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SINUS RHYTHM; SLEEP DISORDERED BREATHING; THYROID DISEASE; WEIGHT REDUCTION; ALGORITHM; COMPLICATION; ELECTROCARDIOGRAPHY; FEMALE; MALE; RISK FACTOR; STROKE;

ADRENERGIC BETA-ANTAGONISTS; ALGORITHMS; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CATHETER ABLATION; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; RISK FACTORS; STROKE;

EID: 84938336574     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.7505     Document Type: Review

References (75)

1. Prystowsky EN, Padanilam BJ, Waldo AL. Atrial fibrillation, atrial flutter, and atrial tachycardia. In: Fuster V, Walsh RA, Harrington RA, et al, eds. Hurst's The Heart. 13th ed. New York, NY: McGraw Hill; 2011:963-986.
2. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society [published correction appears in Circulation. 2014;130(23):e272-e274]. Circulation. 2014;130(23):e199-e267.
3. Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA. 2015;313 (19):1950-1962.
4. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986;57(8):563-570.
5. Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation. 2004;110(3): 247-252.
6. Shen MJ, Choi EK, Tan AY, et al. Neural mechanisms of atrial arrhythmias. Nat Rev Cardiol. 2012;9(1):30-39.
7. Nishida K, Datino T, Macle L, Nattel S. Atrial fibrillation ablation: translating basic mechanistic insights to the patient. J Am Coll Cardiol. 2014;64 (8):823-831.
8. Coumel P, Attuel P, Lavallée J, Flammang D, Leclercq JF, Slama R. Syndrome d'arythmie auriculaire d'origine vagale [in French]. Arch Mal Coeur Vaiss. 1978;71(6):645-656.
9. Scherf D, Romano FJ, Terranova R. Experimental studies on auricular flutter and auricular fibrillation. Am Heart J. 1948;36(2):241-251.
10. Cheung DW. Electrical activity of the pulmonary vein and its interaction with the right atrium in the Guinea-pig. J Physiol. 1981;314:445-456.
11. Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-666.
12. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Am Heart J. 1964;67:200-220.
13. Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63(22):2335-2345.
14. Narayan SM, Krummen DE, Rappel WJ. Clinical mapping approach to diagnose electrical rotors and focal impulse sources for human atrial fibrillation. J Cardiovasc Electrophysiol. 2012;23(5):447-454.
15. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM. Treatment of atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol. 2012;60(7): 628-636.
16. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310(19):2050-2060.
17. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64(21):2222-2231.
18. Pathak TK, Middeldorp ME, Meredith M, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159-2169.
19. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005;293 (21):2634-2640.
20. Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008;118(24): 2498-2505.
21. Wilber DJ, Pappone C, Neuzil P, et al; ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010;303(4):333-340.
22. Packer DL, Kowal RC, Wheelan KR, et al; STOP AF Cryoablation Investigators. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013;61(16):1713-1723.
23. Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012; 367(17):1587-1595.
24. Mont L, Bisbal F, Hernández-Madrid A, et al; SARA investigators. Catheter ablation vs antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J. 2014;35(8):501-507.
25. Morillo CA, Verma A, Connolly SJ, et al; RAAFT-2 Investigators. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014;311(7):692-700.
26. Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833.
27. Van Gelder IC, Hagens VE, Bosker HA, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-1840.
28. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, et al. Rate-and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014;160(11):760-773.
29. Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. Pacing Clin Electrophysiol. 2013;36(1):122-133.
30. Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med. 2012;172(13):997-1004.
31. Prystowsky EN, Padanilam BJ. Preserve the brain: primary goal in the therapy of atrial fibrillation. J Am Coll Cardiol. 2013;62(6):540-542.
32. Bunch TJ, Weiss JP, Crandall BG, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm. 2010;7(4):433-437.
33. Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174(1):107-114.
34. Trulock KM, Narayan SM, Piccini JP. Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation. J Am Coll Cardiol. 2014;64(7):710-721.
35. Roy D, Talajic M, Nattel S, et al; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667-2677.
36. Hsu LF, Jaïs P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351(23):2373-2383.
37. Gentlesk PJ, Sauer WH, Gerstenfeld EP, et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18(1):9-14.
38. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) [published correction appears in J Am Coll Cardiol. 2007;50(6):562]. J Am Coll Cardiol. 2006;48(4): 854-906.
39. Verma A, Cairns JA, Mitchell LB, et al; CCS Atrial Fibrillation Guidelines Committee. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30(10):1114-1130.
40. Prystowsky EN. The history of atrial fibrillation: the last 100 years. J Cardiovasc Electrophysiol. 2008;19(6):575-582.
41. Prystowsky EN. Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden cardiac death. Am J Cardiol. 1996;78(8A):35-41.
42. Calkins H, Kuck KH, Cappato R, et al; Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Heart Rhythm. 2012;9(4):632-696.e21.
43. Padanilam BJ, Prystowsky EN. Ablation as first-line therapy for atrial fibrillation-not yet for all. Card Electrophysiol Clin. 2012;3(4):299-304.
44. Lin WS, Tai CT, Hsieh MH, et al. Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. Circulation. 2003;107 (25):3176-3183.
45. Jalife J, Berenfeld O, Mansour M. Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation. Cardiovasc Res. 2002;54(2):204-216.
46. Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol. 2004;43(11):2044-2053.
47. Katritsis DG, Pokushalov E, Romanov A, et al. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol. 2013; 62(24):2318-2325.
48. Narayan SM, Baykaner T, Clopton P, et al. Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with trigger ablation alone: extended follow-up of the CONFIRM trial (Conventional Ablation for Atrial Fibrillation With or Without Focal Impulse and Rotor Modulation). J Am Coll Cardiol. 2014;63(17):1761-1768.
49. Haissaguerre M, Hocini M, Denis A, et al. Driver domains in persistent atrial fibrillation. Circulation. 2014;130(7):530-538.
50. Piccini JP, Lopes RD, Kong MH, Hasselblad V, Jackson K, Al-Khatib SM. Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. Circ Arrhythm Electrophysiol. 2009;2(6):626-633.
51. Brooks AG, Stiles MK, Laborderie J, et al. Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. Heart Rhythm. 2010;7(6):835-846.
52. Ganesan AN, Shipp NJ, Brooks AG, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(2):e004549.
53. Khan AR, Khan S, Sheikh MA, Khuder S, Grubb B, Moukarbel GV. Catheter ablation and antiarrhythmic drug therapy as first-or second-line therapy in the management of atrial fibrillation: systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014;7(5):853-860.
54. ClinicalTrials.gov. NCT00911508: Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA). https://clinicaltrials.gov/ct2/search/advanced. Accessibility verified June 16, 2015.
55. ClinicalTrials.gov. NCT01288352: Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST). https://clinicaltrials.gov/ct2/search/advanced. Accessibility verified June 16, 2015.
56. Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(1): 32-38.
57. Botto GL, Politi A, Bonini W, Broffoni T, Bonatti R. External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements. Heart. 1999;82 (6):726-730.
58. Mittal S, Ayati S, Stein KM, et al. Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. Circulation. 2000;101(11):1282-1287.
59. Page RL, Kerber RE, Russell JK, et al; BiCard Investigators. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol. 2002;39(12):1956-1963.
60. Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med. 1999;340 (24):1849-1854.
61. Gallagher MM, Guo XH, Poloniecki JD, Guan Yap Y, Ward D, Camm AJ. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol. 2001; 38(5):1498-1504.
62. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004; 351(23):2384-2391.
63. Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol. 2002;40(5):926-933.
64. Olshansky B, Rosenfeld LE, Warner AL, et al; AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43(7):1201-1208.
65. Gillis AM, Verma A, Talajic M, Nattel S, Dorian P; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. Can J Cardiol. 2011;27(1):47-59.
66. Kotecha D, Holmes J, Krum H, et al; β-Blockers in Heart Failure Collaborative Group. Efficacy of β-blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235-2243.
67. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol. 2003;42(11):1944-1951.
68. Turakhia MP, Santangeli P, Winkelmayer WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660-668.
69. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation. 2000;101(10):1138-1144.
70. Curtis AB, Worley SJ, Adamson PB, et al; Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK HF) Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368(17):1585-1593.
71. Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. Eur Heart J. 2011;32(19):2420-2429.
72. Ozcan C, Jahangir A, Friedman PA, et al. Sudden death after radiofrequency ablation of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol. 2002;40(1):105-110.
73. Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 1992;69(19): 1570-1573.
74. Van Gelder IC, Wyse DG, Chandler ML, et al; RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? an analysis of pooled data from the RACE and AFFIRM studies. Europace. 2006;8(11):935-942.
75. Van Gelder IC, Groenveld HF, Crijns HJGM, et al; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-1373.